France Pulls the Trigger on GLP-1 Reimbursement

French Health Minister Stéphanie Rist announced on May 28, 2026, that France's social security system will begin reimbursing the cost of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro starting June 15, according to Reuters.

That makes France the first country in the European Union to offer permanent, standard-coverage reimbursement for anti-obesity drugs. Rist said so herself, on French broadcaster TF1: "I am quite proud, because we are the first country in the European Union to provide reimbursement on a permanent basis."

On the surface, this looks significant. But the details reveal a more complicated picture.

Who Actually Qualifies

This is not a free weight-loss drug program for anyone carrying extra pounds.

Eligibility is strict. Patients must have a body mass index of at least 35 with at least one comorbidity — think high blood pressure, Type 2 diabetes — OR a BMI of at least 40 regardless of other conditions, according to Reuters.

Rist put it plainly: these are "people who may be candidates for surgery" to treat obesity. The drugs are positioned as an alternative to bariatric procedures — not a lifestyle convenience.

The official reimbursement rate is 65%. But Rist said "virtually all patients will be fully covered" at 100% because most who qualify will have comorbidities that trigger complete coverage under France's social security rules, according to Euronews.

The Price Tag

Rist estimated the annual cost to French public finances at "around €100 million" — roughly $116 million — at full rollout, according to CNBC TV18.

The target population sits at approximately one million people, per RTE. But Rist was careful to note that doesn't mean a million people get the drugs. It means a million people could theoretically qualify. Who actually gets prescribed them is between patients and their doctors.

Right now, patients in France are paying around €300 per month out of pocket for these injections, according to Reuters. That's €3,600 a year — real money that's kept plenty of people who need the drugs from getting them. As of late January, more than 70,000 patients were already being treated with Mounjaro in France alone, according to Euronews.

Cost Projections Warrant Scrutiny

Most outlets are framing this as a triumphant public health milestone. The headlines lead with "first in Europe" and leave it there.

The €100 million annual cost estimate deserves closer examination. France's own data says roughly 18% of the French population — around 10 million people — are obese, per the 2024 National Epidemiological Survey on Overweight and Obesity cited by Euronews. The EU-wide picture is worse: 51% of adults overweight, 17% obese, according to European Parliament data.

Government healthcare cost projections have a well-documented history of understating eventual real-world spending. When a million people are potentially eligible and the drugs cost €3,600 a year each, the actual expense could climb significantly higher.

If France sets the precedent, other EU governments will face mounting pressure to follow. Drug company executives are already celebrating publicly. Mike Doustdar, president and CEO of Novo Nordisk, called the move evidence of "foresight and maturity of the French system" in emailed comments to Reuters. Etienne Tichit, General Manager of Novo Nordisk France, told Reuters the move "addresses a growing public health challenge." These statements reflect pharmaceutical companies' direct financial interest in government reimbursement programs.

The Broader GLP-1 Landscape

France isn't operating in a vacuum. The UK's National Health Service already offers limited access to GLP-1 drugs, with patients paying a standard prescription fee of £9.90 per item — about $13.26 — or nothing, depending on circumstances, according to The Epoch Times via ZeroHedge. Switzerland and Japan run similar reimbursement schemes.

The European Medicines Agency last week recommended approval of Novo Nordisk's oral Wegovy pill — potentially the first oral weight-loss drug in Europe — which would expand the market further, according to Reuters. Novo Nordisk and Eli Lilly have also launched oral versions in the U.S. market.

The competitive pressure between these two pharma giants is fierce. That competition may eventually push prices down. For now, governments are signing up to subsidize drugs at whatever price the manufacturers have set.

The Bottom Line

Strict eligibility criteria are the right approach. These drugs are for people with serious medical conditions, not anyone who wants to drop 20 pounds before summer. France drew that line clearly.

For severely obese French patients with qualifying conditions, reimbursement will provide meaningful access to drugs that were previously a €300-a-month barrier. That constitutes a legitimate public health development.

The cost to taxpayers, however, is another question. The €100 million estimate is almost certainly a floor rather than a ceiling.